Your Article Summary
See Latest ArticlesSustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients
Alimentary Pharmacology and Therapeutics, 07/01/09
Andriulli A et al. - In decompensated cirrhotic patients, anti-viral therapy with current regimens is feasible and associated with an overall SVR rate of 35.1%. Treatment ought to be pursued among patients who attain an EVR, and maintain a full course and dosage of therapy.
Related Articles
Emergence of hepatitis C virus genotype 4: phylogenetic analysis reveals three distinct epidemiological profiles
Journal of Clinical Microbiology, 10/02/09
Relevance Score: 93%
CD81 expression in peripheral blood lymphocytes before and after treatment with interferon and ribavirin in HIV/HCV coinfected patients
HIV Medicine, 10/01/09
Relevance Score: 93%
Serum concentrations of interleukin 1î², cxcl10, and interferon-î³ in mixed cryoglobulinemia associated with hepatitis c infection
Journal of Rheumatology, 11/20/09
Relevance Score: 91%
Health-related quality of life in dialysis patients with HCV infection
The International Journal of Artificial Organs, 10/30/09
Relevance Score: 91%
Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection
Journal of Viral Hepatitis, 10/13/09
Relevance Score: 89%
Today in Gastroenterology...keeping you current
Receive free subspecialty "5-minute updates" via email
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
Investigational New Drugs, 12/17/09
Molecular chemoprevention of colorectal malignancy by mesalazine
Alimentary Pharmacology and Therapeutics, 12/17/09
Distribution of advanced neoplasia according to polyp size at screening colonoscopy
Alimentary Pharmacology and Therapeutics, 12/17/09